415 related articles for article (PubMed ID: 24925196)
1. Gastrointestinal stromal tumors, version 2.2014.
von Mehren M; Randall RL; Benjamin RS; Boles S; Bui MM; Casper ES; Conrad EU; DeLaney TF; Ganjoo KN; George S; Gonzalez RJ; Heslin MJ; Kane JM; Mayerson J; McGarry SV; Meyer C; O'Donnell RJ; Pappo AS; Paz IB; Pfeifer JD; Riedel RF; Schuetze S; Schupak KD; Schwartz HS; Van Tine BA; Wayne JD; Bergman MA; Sundar H
J Natl Compr Canc Netw; 2014 Jun; 12(6):853-62. PubMed ID: 24925196
[TBL] [Abstract][Full Text] [Related]
2. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
[TBL] [Abstract][Full Text] [Related]
3. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
Hong JL; Li J; Li J; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
[TBL] [Abstract][Full Text] [Related]
4. Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype.
Judson IR
J Clin Oncol; 2008 Nov; 26(33):5322-5. PubMed ID: 18955449
[No Abstract] [Full Text] [Related]
5. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
7. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
8. Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
Gao J; Tian Y; Li J; Sun N; Yuan J; Shen L
Med Oncol; 2013 Jun; 30(2):522. PubMed ID: 23456621
[TBL] [Abstract][Full Text] [Related]
9. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
10. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Italiano A; Bui B
Bull Cancer; 2008 Jan; 95(1):107-16. PubMed ID: 18230576
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
Wang WL; Conley A; Reynoso D; Nolden L; Lazar AJ; George S; Trent JC
Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1():S15-24. PubMed ID: 21181476
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
[TBL] [Abstract][Full Text] [Related]
13. Perioperative treatment of gastrointestinal stromal tumors.
Fernandes Gdos S; Blanke CD; Freitas D; Guedes R; Hoff PM
Oncology (Williston Park); 2009 Jan; 23(1):54-61. PubMed ID: 19283922
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.
Yoon DH; Ryu MH; Ryoo BY; Beck M; Choi DR; Cho Y; Lee JL; Chang HM; Kim TW; Kang YK
Invest New Drugs; 2012 Apr; 30(2):819-27. PubMed ID: 21104107
[TBL] [Abstract][Full Text] [Related]
15. KIT mutations in GIST.
Fletcher JA; Rubin BP
Curr Opin Genet Dev; 2007 Feb; 17(1):3-7. PubMed ID: 17208434
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathobiology of gastrointestinal stromal sarcomas.
Corless CL; Heinrich MC
Annu Rev Pathol; 2008; 3():557-86. PubMed ID: 18039140
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal stromal tumors.
Antonescu C
Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
[TBL] [Abstract][Full Text] [Related]
18. [Gastrointestinal stromal tumors: evolution of a tumor concept from unclassifiable neoplasms to targeted molecular therapy].
Agaimy A; Schneider-Stock R
Pathologe; 2010 Mar; 31(2):115-22. PubMed ID: 19949796
[TBL] [Abstract][Full Text] [Related]
19. Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib.
Murray M; Hatcher H; Jessop F; Williams D; Carroll N; Bulusu R; Judson I
Pediatr Blood Cancer; 2008 Feb; 50(2):386-8. PubMed ID: 17729245
[TBL] [Abstract][Full Text] [Related]
20. Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.
Blay JY; Reichardt P
Expert Rev Anticancer Ther; 2009 Jun; 9(6):831-8. PubMed ID: 19496720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]